Skip to main content
NewslettersWatchlist

Quantum Biopharma Ltd Cls B Subordinate Voting S(QNTM-CN)
CSE

Today's Change
Delayed Last Update
Day Low6.5500
Day High6.5500
Open:6.5500
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
the globe and mail
the globe and mail

Quantum BioPharma sues over alleged stock spoofing

Broker-dealer units of RBC, TD failed to stop price manipulation, biopharmaceutical firm says
ACCESSWIRE
Quantum Biopharma (NASDAQ:QNTM) Posts Link on Its Website to Access the Filed Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
Newsfile
Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
Newsfile
Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South America
Newsfile
Quantum BioPharma Closes Private Placement Offering
ACCESSWIRE
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis
Newsfile
FSD Pharma Completes Name Change to Quantum BioPharma and 65:1 Consolidation - Trading Under New Ticker Symbol "QNTM"

Profile

Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.